Dr. Kurian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Palo Alto, CA 94305Phone+1 650-723-4000
Education & Training
- Stanford University School of MedicineM.Sc., 2004 - 2006
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2002 - 2003
- Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2002
- Harvard Medical SchoolClass of 1999
- Stanford UniversityB.A., 1991 - 1995
Certifications & Licensure
- CA State Medical License 2002 - 2025
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples Start of enrollment: 2001 Aug 01
Publications & Presentations
PubMed
- 36 citationsPatterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004–2007Allison W. Kurian, Daphne Y. Lichtensztajn, Theresa H.M. Keegan, Rita W. Leung, Sarah J. Shema
Breast Cancer Research and Treatment. 2013-01-01 - 10 citationsCare after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations.Denise R Nebgen, Susan M Domchek, Joanne Kotsopoulos, Joanne A de Hullu, Emma J Crosbie
BJOG. 2023-11-01 - 179 citationsAssociation of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012Sylvia K. Plevritis, Diego F. Munoz, Allison W. Kurian, Natasha K. Stout, Oguzhan Alagoz
JAMA. 2018-01-09
Journal Articles
- Association of Risk-Reducing Salpingo-Oophorectomy with Breast Cancer Risk in Women with BRCA1 and BRCA2 Pathogenic VariantsMary B Daly, Sarah Colonna, Saundra S Buys, Allison W Kurian, JAMA Oncology
- Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer—ReplyAllison W Kurian, Steven J Katz, JAMA
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor SequencingWilliam J Gradishar, Al B Benson, Massimo Cristofanilli, Allison W Kurian, Value in Health
- Join now to see all
Lectures
- Breast cancer treatment according to pathogenic variants in cancer susceptibility genes in a population-based cohort.ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
- Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women’s Health Initiative.ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Genetic testing and results in population-based breast cancer patients and ovarian cancer patients.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Authored Content
- From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor SequencingAugust 2018
Press Mentions
- Genetic Tests Provide Treatment Opportunities and Confusion for Breast Cancer PatientsOctober 21st, 2024
- Many Breast Cancer Survivors with Indications for Genetic Testing Do Not Receive ItJuly 24th, 2024
- Antibiotics After Breast Cancer Linked to Poorer Survival, Stanford Medicine-Led Study FindsApril 18th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: